Researchers study the effect of authorized generics on innovation and market competition

A report released by the Congressional Research Service highlights the potential impact of authorized generics on innovation and market competition. The issue of authorized generics, or the practice of having pharmaceuticals marketed by brand-name drug companies under generic names, has garnered mixed responses regarding its potential impacts. This report reviews the work of previous commentators and offers its own observations in light of recent legislative proposals and judicial decisions. To view a copy of this report, click here.